Resistance to empirical β-lactams recommended in febrile neutropenia guidelines in Gram-negative bacilli bloodstream infections in Spain: a multicentre study. (25th April 2022)

• Record Type: Journal Article
• Authors: Chumbita, Mariana; Puerta-Alcalde, Pedro; Yáñez, Lucrecia; Cuesta, Maria Angeles; Chinea, Anabelle; Español Morales, Ignacio; Fernández Abellán, Pascual; Gudiol, Carlota; Guerreiro, Manuel; González-Sierra, Pedro; Rojas, Rafael; Sánchez Pina, José María; Sánchez Vadillo, Irene; Varela, Rosario; Vázquez, Lourdes; Lopera, Carlos; Monzó, Patricia; Garcia-Vidal, Carolina
• Is Part Of: Journal of antimicrobial chemotherapy. Volume 77:Number 7(2022)
• Page Start: 2017
• Page End: 2023
• Publication Date: 2022-04-25
• Subjects: Anti-infective agents -- Periodicals; Chemotherapy -- Periodicals; 615.58
• DOI: 10.1093/jac/dkac135
• Languages: English
• ISSNs: 0305-7453

Abstract

Abstract: Objectives: To describe current resistance to the β-lactams empirically recommended in the guidelines in bloodstream infection (BSI) episodes caused by Gram-negative bacilli (GNB). Methods: Retrospective, multicentre cohort study of the last 50 BSI episodes in haematological patients across 14 university hospitals in Spain. Rates of inappropriate empirical antibiotic therapy (IEAT) and impact on mortality were evaluated. Results: Of the 700 BSI episodes, 308 (44%) were caused by GNB, mainly Escherichia coli (141; 20.1%), Klebsiella spp. (56; 8%) and Pseudomonas aeruginosa (48; 6.9%). Among GNB BSI episodes, 80 (26%) were caused by MDR isolates. In those caused by Enterobacterales, 25.8% were ESBL producers and 3.5% were carbapenemase producers. Among P. aeruginosa BSI episodes, 18.8% were caused by MDR isolates. Overall, 34.7% of the isolated GNB were resistant to at least one of the three β-lactams recommended in febrile neutropenia guidelines (cefepime, piperacillin/tazobactam and meropenem). Despite extensive compliance with guideline recommendations (91.6%), 16.6% of BSI episodes caused by GNB received IEAT, which was more frequent among MDR GNB isolates (46.3% versus 6.1%; P < 0.001). Thirty day mortality was 14.6%, reaching 21.6% in patients receiving IEAT. Conclusions: Current resistance to empirical β-lactams recommended in febrile neutropenia guidelines is exceedingly high and IEAT rates are greater than desired. There is an urgent need to adapt guidelines to current epidemiology and better identify patients with a high risk of developing MDR GNB infection.